このエントリーをはてなブックマークに追加
ID 62412
FullText URL
Author
Matsumoto, Kazuyuki Department of Gastroenterology and Hepatology, Okayama University Hospital ORCID Kaken ID publons
Kato, Hironari Department of Gastroenterology and Hepatology, Okayama University Hospital ORCID Kaken ID researchmap
Kitano, Masayuki Second Department of Internal Medicine, Wakayama Medical University
Hara, Kazuo Gastroenterology, Aichi Cancer Center
Kuwatani, Masaki Gastroenterology and Hepatology, Hokkaido University Hospital
Ashida, Reiko Second Department of Internal Medicine, Wakayama Medical University
Takenaka, Mamoru Department of Gastroenterology and Hepatology, Kindai University
Yamazaki, Tatsuhiro Department of Gastroenterology and Hepatology, Okayama University Hospital
Sakurai, Jun Center for Innovative Clinical Medicine, Okayama University Hospital
Yoshida, Michihiro Center for Innovative Clinical Medicine, Okayama University Hospital
Okada, Hiroyuki Department of Gastroenterology and Hepatology, Okayama University Hospital Kaken ID publons researchmap
Abstract
Introduction The management of small pancreatic neuroendocrine neoplasms (PNENs) remains controversial. The standard treatment for PNENs is surgical resection; however, invasiveness of surgical procedure remains higher and the incidence of postoperative adverse events is still high. Recently, the efficacy and safety of endoscopic ultrasonography (EUS)-guided ethanol injection for small PNENs has been preliminarily demonstrated. Thus, a multicentre prospective study is being conducted to evaluate the efficacy and safety of EUS-guided ethanol injection therapy for small PNENs. Methods and analysis The major eligibility criteria are the presence of pathologically diagnosed grade (G) 1 tumour, a tumour size of <= 15 mm and non-functional PNEN or insulinoma. For treatment, we will use a 25-gauge needle and pure ethanol. Contrast-enhanced CT (CE-CT) will be performed on postoperative day 3-5, and if enhanced areas of the tumour are still apparent, an additional session is scheduled during the same hospitalisation period. We set the total amount of ethanol per session to 2 mL. To evaluate the efficacy and safety, CE-CT will be performed at 1 and 6 months after treatment. The primary endpoint is the percentage of subjects who achieved all of the following evaluated points. Efficacy will be evaluated based on the achievement of complete ablation (defined as no enhanced area within the tumour on CE-CT) at 1 and 6 months. Safety will be evaluated based on the avoidance of severe adverse events within 1 month after treatment, continuing severe pancreatic fistula at 1 month after treatment and the incidence and/or exacerbation of diabetes mellitus at 6 months after treatment. Ethics and dissemination This protocol has been approved by Okayama University Certified Review Board (approval number. CRB19-007). The results will be submitted to peer-reviewed journals and will be presented at international conferences.
Keywords
gastroenterology
endoscopy
pancreatic disease
Published Date
2021
Publication Title
BMJ Open
Volume
volume11
Issue
issue7
Publisher
BMJ Publishing Group
Start Page
e046505
ISSN
2044-6055
Content Type
Journal Article
language
英語
OAI-PMH Set
岡山大学
Copyright Holders
© Author(s) (or their employer(s)) 2021.
File Version
publisher
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.1136/bmjopen-2020-046505
License
http://creativecommons.org/licenses/by-nc/4.0/